Assistance Publique Hopitaux De Paris — Sponsor Intelligence | 264 EU Trials

Filter these 264 trials by condition, phase, country and more.

Open in Search →

264 Registered trials

134 Recruiting

61 Completed trials

13 Countries active

346 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 137 Phase II/III: 14 Phase II: 72 Phase I/II: 11 Phase III/IV: 6 Phase IV: 12 Phase I: 5 Phase I (Other): 2 Phase I (FiH): 5

Oversight events:

1 serious breach 12 temporary halts 9 urgent safety measures 2 unexpected events 8 corrective measures across 24 trials

View oversight register →

100%

61 of 61 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Sickle cell disease 3 Cutaneous T-cell lymphoma 2 Acute kidney injury 2 Giant cell arteritis 2 Granulomatosis with polyangiitis 2 Autism spectrum disorder 2 Ischaemic stroke 2 Atrial fibrillation 1 Neuromyopathy 1 B-cell lymphoma 1 Primary biliary cholangitis 1 Cardiac arrest 1

Top IMPs

ALLOGENEIC FAECAL MICROBIOTA, POOLED 10 SODIUM CHLORIDE 7 PLACEBO 6 PREDNISONE 5 ANAKINRA 4 CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS 4 RITUXIMAB 4 TOCILIZUMAB 4 ALDESLEUKIN 3 BARICITINIB 3 COLCHICINE 3 METHOXYFLURANE 99.9% 3

All trials — page 4

264 total

Remyelination in Multiple Sclerosis: a PET-MR longitudinal study investigating individual profiles of myelin repair and the contribution of … Recruiting

2024-512761-13-00 Phase III 1 country
AMUNDSEN - Acute Myocardial infarction Upbound to percutaneous coronary intervention, immediately (STEMI) or in the Next three Days (NSTEMI)… Recruiting

2024-518195-31-00 Phase IV 5 countries EVOLOCUMAB
A multi-center phase III randomized study comparing continuous versus fixed duration therapy with Daratumumab, Lenalidomide, and Dexamethaso… Recruiting

2024-511855-16-00 Phase III 1 country DARATUMUMAB
STARS (Secukinumab in TAkayasu ARteritiS) Recruiting

2024-516215-24-00 Phase II 1 country SECUKINUMAB
DIMREATOX study - Reduction in digestive absorption of toxic substances by combined digestive decontamination in intensive care - randomized… Recruiting

2024-518739-12-00 Phase II 1 country CHARCOAL, ACTIVATED; SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLOR…
Evaluation of the efficacy of corticosteroids in septic arthritis in adults: Randomized double-blind controlled trial [CORSAR] Recruiting

2025-522193-37-00 Phase III 1 country PREDNISONE
ORIAMI Recruiting

2023-508249-42-00 Phase III 1 country GENTAMICIN; METRONIDAZOLE; SODIUM CHLORIDE
COMMODITIES : Comparison of initial dual oral COMbination therapy to MOnotherapy in pulmonary arterial hypertension with cardiovascular como… Recruiting

2023-509891-40-00 Phase III 1 country AMBRISENTAN
Inhaled isoflurane for SEdation of invasively ventilated PaTIents with cardiogenic shock on extracOrporeal membrane oxygeNation (INSEPTION) Recruiting

2023-510261-94-00 Phase III 1 country ISOFLURANE
BCS-ORL - Evaluation of the superficial cervical plexus block in oncological throat and neck surgery Recruiting

2024-510942-15-00 Phase III 1 country
DIAMOND Study - DIrect oral anticoagulant for Antithrombotic Management Of aortic bioprothesis implanted patients for valvular heart Disease… Recruiting

2024-516643-64-00 Phase III 1 country APIXABAN
RUBIKID - Dynamic 82-Rb positron emission tomography (PET) for the grading of KIDney carcinoma Recruiting

2024-514085-39-00 Phase II 1 country
A Phase 1/2 Open Label Cohort Comparative Study Evaluating the Efficacy and the safety of Gene Therapy of the Sickle Cell Disease by Transpl… Recruiting

2025-521257-17-00 Phase I (FiH) 1 country DREAM01
INFINITY - Effect of interferon gamma as a treatment for post-aggressive immunosuppression in intensive care units, a randomized Bayesian do… Recruiting

2023-506725-11-00 Phase III 1 country RECOMBINANT HUMAN INTERFERON GAMMA 1B
A multicenter phase 2 single-arm proof-of-concept trial assessing the efficacy and safety of Obinutuzumab in the treatment of non-infectious… Recruiting

2023-508930-33-00 Phase II 1 country OBINUTUZUMAB
NUCastle - Nintedanib treatment in Unicentric Castleman disease Recruiting

2023-510253-42-00 Phase II 1 country NINTEDANIB
CombiChronoS - Effectiveness of a Combination of Chronotherapeutics for the Treatment of Major Depressive Episode (MDE) with Insomnia: A Mul… Recruiting

2024-516371-32-00 Phase III 1 country MELATONIN
Safety of Atezolizumab/Bevacizumab in liver transplanted patients with advanced hepatocellular carcinoma (IMMUNO-TH) Recruiting

2024-514400-14-00 Phase II 1 country
ANACOMP. A RANDOMIZED PHASE III MULTICENTER TRIAL COMPARING THE EFFICACY AND SAFETY OF ANAKINRA VERSUS INTRAVENOUS IMMUNOGLOBULIN (IVIG) RET… Recruiting

2024-516244-25-00 Phase III 1 country ANAKINRA; HUMAN NORMAL IMMUNOGLOBULIN
GRAALL 2024 - A 3-cohort Randomized Study evaluating the role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Tran… Recruiting

2024-511437-35-00 Phase II/III 2 countries BLINATUMOMAB; ISATUXIMAB; PONATINIB
Impact Of The Gut Microbiota On Host Cells Energy Metabolism in Health And In Inflammatory Bowel Recruiting

2024-513330-38-00 Phase II 1 country GENTAMICIN SULFATE
OBI-WAN : Obinutuzumab for remission induction in patients with relapsing PR3-ANCA granulomatosis with polyangiitis (Wegener’s). Phase 2 pro… Recruiting

2022-501557-36-00 Phase II 1 country OBINUTUZUMAB
INFLANET - A French Network for PET imaging of neuroinflammation in MS Recruiting

2023-510304-53-00 Phase II/III 1 country N,N-DIETHYL-2-(2-(4-(2[(18)F]-FLUOROETHOXY)PHENYL)5,7DIMETHYLPYRAZOLO[1,5A]PYRIM…
RHIBOT II - Medium- and long-term efficacy of two ultrasound-guided intra-articular injections of onabotulinumtoxinA (Botox®) combined with … Recruiting

2024-515028-35-00 Phase III 1 country BOTULINUM TOXIN TYPE A

Showing 73–96 of 264 trials

← All sponsors A–Z